The cure for arthritis - you’d think we were after the Holy Grail or something. It seemed so incredibly difficult and elusive. After all, medical science has been searching for it for centuries with nothing more to show than a few pain relievers and anti-inflammatory drugs. Nothing before even came close to being a cure.

Medical professionals loathe using the word miracle even in the face of the most miraculous of circumstances. Nevertheless, the word keeps cropping up in physicians’ reports about CMO. Dr. William C. Douglas titled his article A New “Miracle Cure” for Arthritis in the newsletter Second Opinion. Dr. Douglas Hunt used the word in his book Boom You’re Well. And patients call it miraculous all the time. Even medical doctors who’ve sought relief from their own pain and suffering through various other remedies have used the expression liberally.

A revolutionary discovery - buried since early 1970’s
Back in the early 1970s a researcher in the employ of the U.S. Government National Institutes of Health (NIH) made a discovery. In a certain strain of laboratory rats he found a substance that not only made animals immune to getting arthritis, but also cured afflicted animals. The substance, originally extracted from ground up Swiss Albino Mice, is called cetylmyristoleate.

However, when the researcher reported his remarkable findings to his superiors in an attempt to secure funding for additional research, his request was mysteriously denied. Nevertheless, struggling along without authorization, he continued his studies and reported further successes. Strangely, not only were his requests for funding continuously denied, all of his accomplishments went completely unrecognized. Though they never said so directly, it was as though the NIH wanted him to abandon the project completely. Discouraged though he was, he still continued his research as best he could with absolutely no funding at all. When he retired about a decade later, since even the mere existence of his work went completely unacknowledged by the NIH, he took his discovery with him and continued the research on his own. And well he deserved to do so. Had he not, his discovery may never have come to light.

It has been reported that some time later, one by one he went to three different major pharmaceutical companies offering to share his discovery. One by one, his offers were rejected - not for lack of effectiveness, but because the product was derived from natural sources it could not be patented in a way to exclusively retain all the profits. The companies couldn’t care less about the fact that it worked, only that they couldn’t protect it from being manufactured by some competing company. Nor did they express any interest in funding further research on the project.

One could also speculate on the likelihood that by making available a product that potentially reverses the arthritic process permanently, it would kill their annual multi-billion dollar sales of existing arthritis products - all of which must be taken repeatedly for the rest of the arthritis victims’ lives. Quite understandably, of course, the pharmaceutical companies love products that lead to a lifetime of repeat sales. After its rejection by the pharmaceutical companies the project lay fallow for several years. No further attempts were made to explore its potential.

The chain of events that followed has never been made crystal clear. It has been reported that as some years passed, the researcher himself began to suffer terribly from arthritis and was receiving conventional medical therapy to treat it. It is important to note that despite the fact that he had explored the safety and effectiveness of his discovery on lower animals at the NIH, research had never reached the level of testing on higher animals. But once his arthritis reached excruciating extremes and his physician told him that he was beyond any effective help, the researcher decided to take a risk. He brewed up a batch of cetylmyristoleate at home and injected himself. Thus, he became the first person ever to receive the substance as a test of the discovery on human beings. We honor his courage.

It was a historic moment. He began to feel symptomatic relief the very next day, and soon he reached a point where he experienced total reversal of his arthritis. His doctor was astonished when he subsequently examined his patient and heard the whole story of the discovery.

The doctor was so impressed that he persuaded him to write an account of his research project. The doctor promised to help him get it published in the Journal of Pharmaceutical Sciences, hoping that the article might stimulate someone into continuing the exploration of the project. Then, early in 1995, a few months after the article appeared, that’s exactly what happened. The San Diego Clinic embarked on a project to develop the discovery into a usable product.

But long before that, it seems that several years had intervened between the self-injection and the actual publication of the article. Meanwhile, it has been reported, even though the substance was provided quite informally to a couple hundred more arthritis victims with astounding success, there was no formal progress in research or development.

The journal article itself didn’t seem to stimulate much interest either. Perhaps that’s because it was only three pages long and dealt solely with mouse model studies. Besides, it was reporting on research that took place over twenty years before. Perhaps the readers thought there couldn’t be much value to something that had lain dormant so very long. Or maybe they thought there must have been more recent research that refuted the early findings. Nor did the article provoke questions about why it had been ignored by the NIH and how it came to be buried for so long - except in one instance.

It’s not easy turning a discovery into a miracle
When a research associate of the San Diego Clinic found the report, he immediately recognized its potential. Intense research on arthritis by that group had been ongoing for several years, spurred on in part by the personal interest of the clinic’s director who himself was suffering from very severe osteoarthritis in both knees.

It wouldn’t take long to produce a small quantity for some preliminary testing, but there were drawbacks. The original substance was effective as an injectable, but to make it readily available to the public, an oral form would have to be developed. As an orally administered product the original injectable form often produced diarrhea or upset the stomach. It was heavy oil that resulted a gooey mess when put into capsules. Furthermore, not only was it difficult to digest, its bioavailability was very low. Low bioavailability results in very little of a product actually being assimilated in a form that’s effective for its purpose in the body. That means more product is needed to accomplish its mission. And that drives up the cost, which was already very high as a result of the complexity in producing the substance.

Once the decision was made to try to develop an improved product, the original researcher was approached with an offer to join in the forthcoming project. For reasons not clearly expressed, he refused. Perhaps, as a result of the previous rejections, he felt there was no commercial value to the substance. Or he may have had other considerations. Whatever the reason, he rejected the offer.

What the new researchers were after would have to be quite different from the original, yet retain or improve on its effectiveness. Thanks to the genius of the biochemist that found the journal article, all of their goals were met. He was able to develop a product with high bioavailability when taken orally. Furthermore, it did not upset the stomach. Nor did it disturb the intestinal tract, except in the most sensitive persons. And he managed to overcome one of the biggest hurdles: come up with a manufacturing process that was cost-effective. It was an amazing feat.

Finally, a product for the public
The result was cerasomal-cis-9-cetylmyristoleate, which bears the commercial name of CMO. Now CMO is quite different from the unmodified cetylmyristoleate which produces nausea, is so hard to digest, and has such a low level of bioavailability. In CMO, the cetylmyristoleate is phase stabilized using certain cerasomal technologies which makes it so much easier to assimilate through the intestine, disposes of the nausea problem, and gives it enormously higher levels of bioavailability. It also results in an end product that is a waxy solid rather than a messy oily liquid, making it much easier and neater to capsule. The end result was the commercially viable product available today: CMO. And that’s the product so many people are calling a miracle because it has been so effective where all else has failed.

There are cases where people had been unable to walk up a flight of stairs for years, but they’re doing it now - and painlessly, thanks to CMO. There are numerous cases where conventional treatments had reached a point where they were no longer of any benefit at all - yet CMO relieved all their symptoms. Many were very severe cases. Actually, there have been so many successes with extreme cases that they’re not at all uncommon any more. Doctors keep reporting new ones every week. The specific details of many cases, some quite ordinary and some quite fascinating, will be reported in following chapters.

A warning about counterfeit CMO!
CMO has been so effective that there are even several counterfeit versions being produced by unscrupulous criminals preying upon unsuspecting arthritis victims and health product dealers. Their labels may even claim to be the original or authentic product, but they are not CMO. One of the following chapters describes most of these counterfeit products and explains how to verify your product source.

A Federal Court in California has sent a clear message that it recognizes the authenticity of CMO and will not tolerate the infringement of counterfeiters upon the authentic product. The United States District Court in Orange, California awarded a half million dollars in damages in a judgment against Advanced Labs of Redding, California as a result of a suit filed against them alleging trademark infringement, false advertising, and unfair competition, claiming that those practices resulted in consumer confusion and loss of sales of authentic CMO products.

The CMO mark has been used since November 1995 to clearly and specifically identify the proprietary cerasomal-cis-9- cetylmyristoleate product. CMO is a natural immunomodulator used by people suffering from such ailments as arthritis, Crohn’s disease, carpal tunnel syndrome, fibromyalgia, emphysema, migraine headaches, prostate inflammation, and several other ailments with autoimmune involvement.